The Cooper Companies, Inc. $COO Position Lessened by 2Xideas AG

2Xideas AG decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 19.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,044 shares of the medical device company’s stock after selling 17,925 shares during the period. 2Xideas AG’s holdings in Cooper Companies were worth $5,340,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Cooper Companies during the 1st quarter valued at about $33,000. J.Safra Asset Management Corp increased its holdings in Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Cooper Companies during the first quarter valued at approximately $40,000. Assetmark Inc. lifted its stake in Cooper Companies by 357.8% in the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 483 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Cooper Companies by 36.6% in the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after acquiring an additional 257 shares during the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Trading Down 4.1%

Cooper Companies stock opened at $78.04 on Tuesday. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $100.47. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The firm has a market capitalization of $15.52 billion, a PE ratio of 41.51, a PEG ratio of 1.94 and a beta of 1.05. The business’s 50-day simple moving average is $72.50 and its 200-day simple moving average is $71.60.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has authorized a share repurchase plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on COO. JPMorgan Chase & Co. raised their price target on shares of Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a report on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a research report on Monday, December 1st. Wells Fargo & Company boosted their price target on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday. Barclays reiterated an “overweight” rating and set a $91.00 price target on shares of Cooper Companies in a research note on Monday. Finally, Robert W. Baird increased their price objective on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.15.

Insider Activity

In related news, Director Lawrence Erik Kurzius bought 2,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were acquired at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the transaction, the director owned 5,777 shares of the company’s stock, valued at $395,089.03. The trade was a 52.95% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.98% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.